A 34‐year‐old man with non‐obstructive apical hypertrophic cardiomyopathy (RCD code: III‐2A.1)
Kitaoka H, Doi Y, Casey SA, et al. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol. 2003; 92: 1183–1186.
Hada Y, Sakamoto T, Amano K, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol 1987; 59: 183–184.
Savage DD, Castelli WP, Abbott RD, et al. Hypertrophic cardiomyopathy and its markers in the general population: the great masquerader revisited: the Framingham Study. J Cardiovasc Ultrason 1983; 2: 41–47.
Maron BJ, Peterson EE, Maron MS, et al. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. 1994; 73: 577–580.
Podolec P, Kabłak-Ziembicka A, Komar M, et al. Rare Cardiovascular Diseases. From classification to clinical examples. Medycyna Praktyczna 2013; 205–209.
Cirino AL; Ho, C. Hypertrophic Cardiomyopathy Overview. GeneReviews 2008.
Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 201–211.
Elliot PM, Anderson B, Arbustini A, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2007; 29: 270–277.
Yusuf SW, Bathina JD, Banchs J, et al. Apical hypertrophic cardiomyopathy. World Journal of Cardiology. 2011; 3: 256–259.
Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011; 124: 40–47.
Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 42: 1687–1713.
Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000; 36: 2212–2218.
Eriksson MJ, Sonnenberg B, Woo A, et al. Long -term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 638–645.
Arad M, Penas-Lado M, Monserrat L, et al. Gene mutations in apical hypertrophic cardiomyopathy. Circulation 2005; 112: 2805–2811.
Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000; 102: 858–864.
Elliott PM, Anastasakis A, Borger MA, et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35: 2733–2779.
Rubiś P, Biernacka-Fijałkowska B, Khachatryan L, et al. Comparison of two European models estimating risk of sudden cardiac death in hypertrophic cardiomyopathy. Acta Cardiologica 2017; 72: 446–452.
- There are currently no refbacks.